Radiopharm Theranostics Ltd ADR Dossier - Source-backed chat

Radiopharm Theranostics Ltd ADR

RADAustralian Securities Exchange

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.83

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.48Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $21.6M

Enterprise Value −$7.5M

Shares Outstanding 14.5M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Radiopharm Theranostics Ltd (ASX: RAD, Nasdaq: RADX) is a clinical-stage biopharmaceutical company developing a highly differentiated pipeline of oncology radiopharmaceuticals. The company's investment thesis is anchored on its multi-platform approach (peptides, small molecules, and monoclonal antibodies) targeting high unmet medical needs such as brain metastases, breast, lung, and prostate cancers. With key clinical readouts expected in mid-to-late 2026, particularly the Phase 2b data for its lead imaging asset RAD 101, Radiopharm is positioned for significant near-term value creation. Recent capital raises and strategic investments from Lantheus have extended the company's cash runway into 2027, mitigating near-term funding risks while it advances its clinical programs.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.68

Mean target$17.32

High · most bullish analyst$30.60

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$6.0015%

The bear case is triggered by clinical or regulatory setbacks. If RAD 101's full Phase 2b data shows a significant drop in concordance or unexpected safety concerns, the path to a Phase 3 registrational trial would be delayed or halted. Additionally, if RAD 202 or RAD 204 encounter dose-limiting toxicities during Phase 1 escalation, or if patient recruitment slows down significantly, the timeline to key milestones will extend. Under this scenario, the company's cash burn would accelerate, forcing highly dilutive equity financing at depressed share prices.

Base CaseCentral scenario

$17.1260%

The base case reflects steady clinical execution in line with current company guidance. RAD 101 meets its primary endpoint in the Phase 2b trial with high concordance, supporting the preparation for a Phase 3 trial. RAD 202 and RAD 204 complete their Phase 1 dose escalations by late 2026 or early 2027, demonstrating acceptable safety and biodistribution. The company utilizes its cash runway (funded into 2027) to achieve these milestones, potentially securing a regional licensing deal or executing a modest, disciplined capital raise to fund Phase 3 development.

Bull CaseUpside scenario

$30.0025%

The bull case assumes outstanding clinical success across all lead programs. RAD 101's Phase 2b full readout confirms >=90% concordance with MRI, triggering a seamless transition into a Phase 3 registrational trial by Q4 2026 and attracting a lucrative global pharmaceutical partnership. Concurrently, RAD 202 and RAD 204 successfully complete their Phase 1 dose escalations by the end of 2026 with favorable safety profiles and strong efficacy signals, while newly initiated trials for RV-01 and RAD 402 progress rapidly. This clinical momentum, combined with non-dilutive funding from partnerships, drives substantial valuation upside.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Highly diversified pipeline of radiopharmaceutical assets targeting multiple distinct oncological pathways (HER2, PD-L1, FASN, B7H3, KLK3).
Lead diagnostic asset RAD 101 has demonstrated strong clinical proof-of-concept with 90% MRI concordance in brain metastases, representing a peak US sales potential of over $500 million.
Strong strategic backing and validation from industry leader Lantheus, which holds a significant equity stake and has licensed multiple assets.
Cash runway secured into 2027 following successful capital raises and strategic investments, providing sufficient funding to reach major clinical milestones.

Key Investment Risks

Clinical development risk: The company's assets are primarily in early-stage (Phase 1/2) clinical trials, which carry high rates of attrition.
Funding risk: As a clinical-stage biotech with no commercial product revenues, the company will require substantial additional capital to fund late-stage trials.
Competitive landscape: The radiopharmaceutical sector is highly competitive, with major pharmaceutical companies actively acquiring and developing competing platforms.

Thesis Invalidation Triggers

RAD 101 Phase 2b full data fails to demonstrate acceptable concordance with MRI or reveals severe safety issues.
Dose-limiting toxicities are observed in the RAD 202 HEAT trial or RAD 204 trial, preventing successful completion of Phase 1 dose escalation.
Lantheus terminates its strategic relationship or fails to participate in future funding rounds, signaling a loss of confidence in the platform.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.